Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Rhea-AI Summary

Artiva Biotherapeutics announced new data presentations for their AlloNK® cell therapy at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in New Orleans this May.

Key highlights:

• New longer-term Phase 1/2 data shows promising results for AlloNK® combined with rituximab in treating relapsed/refractory B-cell non-Hodgkin lymphoma
• Treatment demonstrated prolonged response duration, deep B-cell depletion, and well-tolerated safety profile
• Results support AlloNK's potential for treating B-cell driven diseases in community settings

Two poster presentations are scheduled:

• May 13: AlloNK® Cell Therapy ± Rituximab in Patients with Non-Hodgkin Lymphoma
• May 15: AlloNK manufacturing process scalability and consistency

The presentations highlight Artiva's progress in developing accessible cell therapies for autoimmune diseases and cancers. Abstracts are available on the ASGCT website, with poster copies to be shared on Artiva's website after the presentations.

Positive

• Longer-term Phase 1/2 data shows prolonged duration of response for AlloNK therapy
• Deep B-cell depletion demonstrated in clinical results
• Well-tolerated safety profile reported for AlloNK + rituximab combination
• Manufacturing process shows scalability and consistency
• Potential application in both oncology and autoimmune diseases

Negative

• None.

News Market Reaction

%

1 alert

% News Effect

On the day this news was published, ARTV declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK^® + rituximab for the treatment of B-cell driven diseases in a community setting

Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that the Company will have a poster presentation on new longer-term Phase 1/2 data for AlloNK® (also known as AB-101) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28^th Annual Meeting taking place May 13-17, 2025, in New Orleans, Louisiana. These results demonstrate prolonged duration of response, deep B-cell depletion and a well-tolerated safety profile of AlloNK in combination with rituximab.

In addition, the Company will have a poster presentation featuring the scalability and consistency of the AlloNK manufacturing process.

Details of the presentations are as follows:

Abstract 858 – AlloNK^® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Date/Time: May 13, 2025, 6:00 p.m. – 7:30 p.m. CT

Session Title: Poster Reception

Location: Poster Hall I2

Abstract 1765 – AlloNK: A Scalable and Consistent NK Cell Therapy in Development for Treatment of Oncology and Autoimmune Diseases

Date/Time: May 15, 2025, 5:30 p.m. – 7:00 p.m. CT

Session Title: Poster Reception

Location: Poster Hall I2

Abstracts are currently available on the ASGCT website. Following the presentations, copies will be available on the "Scientific Posters & Publications" section of the “Events & Presentation” page on the Company's website.

About Artiva Biotherapeutics

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK^®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK^® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs. 

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements.  Such forward-looking statements include, without limitation, statements regarding Artiva Biotherapeutics, Inc.’s (the “Company”) participation in the ASGCT 28th Annual Meeting; the content of the Company’s presentations; the potential benefits, accessibility, effectiveness and safety of AlloNK^® + rituximab for the treatment of B-cell driven diseases; and the Company’s expectations regarding timing and availability of data from the Company’s clinical trials.  These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

Source: Artiva Biotherapeutics, Inc.

FAQ

What are the key findings from Artiva's (ARTV) AlloNK Phase 1/2 trial presented at ASGCT 2025?

Artiva's AlloNK trial showed three main results: prolonged duration of response, deep B-cell depletion, and a well-tolerated safety profile when combined with rituximab for treating B-cell non-Hodgkin lymphoma patients.

When will Artiva (ARTV) present their AlloNK data at ASGCT 2025?

Artiva will present two posters at ASGCT in New Orleans: Abstract 858 on May 13, 2025 at 6:00 PM CT and Abstract 1765 on May 15, 2025 at 5:30 PM CT.

What diseases can Artiva's (ARTV) AlloNK treatment potentially target?

AlloNK therapy is being developed to treat B-cell driven diseases, specifically showing promise for relapsed/refractory B-cell non-Hodgkin lymphoma, with potential applications in both autoimmune diseases and cancers.

How is Artiva (ARTV) manufacturing AlloNK cell therapy?

Artiva will present data showing their AlloNK manufacturing process is both scalable and consistent, which is crucial for potential community setting treatments. Details will be shared in Abstract 1765 at ASGCT 2025.

What makes Artiva's (ARTV) AlloNK therapy unique for community settings?

AlloNK therapy stands out for its well-tolerated safety profile and effectiveness when combined with rituximab, making it potentially suitable for community-based treatment settings rather than just specialized centers.